Skip to main content
Erschienen in: Current Hypertension Reports 3/2010

01.06.2010

Renal Nerves in the Maintenance of Hypertension: A Potential Therapeutic Target

verfasst von: Richard E. Katholi, Krishna J. Rocha-Singh, Nilesh J. Goswami, Paul A. Sobotka

Erschienen in: Current Hypertension Reports | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Renal sympathetic efferent and afferent nerves, which lie within and immediately adjacent to the wall of the renal arteries, contribute to the maintenance of hypertension. Because the causative factors of hypertension change over time, denervation of both efferent and afferent renal nerves should result in long-term attenuation of hypertension. The importance of the renal nerves in hypertensive patients can now be defined with the novel development of percutaneous, minimally invasive renal denervation from within the renal artery using radiofrequency energy as a therapeutic strategy. Studies thus far show that catheter-based renal denervation in patients with resistant essential hypertension lowers systolic blood pressure 27 mm Hg by 12 months, with the estimated glomerular filtration rate remaining stable. The decrease in arterial pressure after renal denervation is associated with decreased peripheral sympathetic nervous system activity, suggesting that the kidney is a source of significant central sympathetic outflow via afferent renal nerve activity.
Literatur
1.
Zurück zum Zitat Katholi RE: Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol 1983, 245:F1–F14.PubMed Katholi RE: Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol 1983, 245:F1–F14.PubMed
2.
Zurück zum Zitat Katholi RE: Renal nerves and hypertension: an update. Fed Proc 1985, 44(13):2846–2850.PubMed Katholi RE: Renal nerves and hypertension: an update. Fed Proc 1985, 44(13):2846–2850.PubMed
3.
Zurück zum Zitat DiBona GF: Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertension 2002, 11:197–200.CrossRef DiBona GF: Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertension 2002, 11:197–200.CrossRef
4.
Zurück zum Zitat Campese VM, Kogosov E, Koss M: Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995, 26:861–865.CrossRefPubMed Campese VM, Kogosov E, Koss M: Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995, 26:861–865.CrossRefPubMed
5.
Zurück zum Zitat Ye S, Zhong H, Yanamadala V, Campese VM: Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertension 2002, 15:717–724.CrossRef Ye S, Zhong H, Yanamadala V, Campese VM: Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertension 2002, 15:717–724.CrossRef
6.
Zurück zum Zitat Kopp UC, Cicha MZ, Smith LA: Dietary sodium loading increases arterial pressure in afferent renal-denervated rats. Hypertension 2003, 42(5):968–973.CrossRefPubMed Kopp UC, Cicha MZ, Smith LA: Dietary sodium loading increases arterial pressure in afferent renal-denervated rats. Hypertension 2003, 42(5):968–973.CrossRefPubMed
7.
Zurück zum Zitat Hausberg M, Kosch M, Harmelinck P, et al.: Sympathetic nerve activity in end-stage renal disease. Circulation 2002, 106:1974–1979.CrossRefPubMed Hausberg M, Kosch M, Harmelinck P, et al.: Sympathetic nerve activity in end-stage renal disease. Circulation 2002, 106:1974–1979.CrossRefPubMed
8.
Zurück zum Zitat Joles JA, Koomans HA: Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004, 43:699–706.CrossRefPubMed Joles JA, Koomans HA: Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004, 43:699–706.CrossRefPubMed
9.
Zurück zum Zitat Schlaich MP, Socratous F, Hennebry S, et al.: Sympathetic activation in chronic renal failure: J Am Soc Nephrol 2009, 20:933–939.PubMed Schlaich MP, Socratous F, Hennebry S, et al.: Sympathetic activation in chronic renal failure: J Am Soc Nephrol 2009, 20:933–939.PubMed
10.
Zurück zum Zitat • Grassi G: Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009, 54:690–697. This review article emphasizes how direct recording of efferent postganglionic muscle sympathetic nerve traffic via microneurography and regional norepinephrine spillover techniques has better defined the role of the sympathetic nervous system in the pathophysiology of hypertension. • Grassi G: Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009, 54:690–697. This review article emphasizes how direct recording of efferent postganglionic muscle sympathetic nerve traffic via microneurography and regional norepinephrine spillover techniques has better defined the role of the sympathetic nervous system in the pathophysiology of hypertension.
11.
Zurück zum Zitat Mancia G, Grassi G, Giannattasio, et al.: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999, 34:724–728. Mancia G, Grassi G, Giannattasio, et al.: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999, 34:724–728.
12.
Zurück zum Zitat Charkoudian N, Rabbitts JA: Sympathetic neural mechanisms in human cardiovascular health and disease. Mayo Clin Proc 2009, 84:822–830.CrossRefPubMed Charkoudian N, Rabbitts JA: Sympathetic neural mechanisms in human cardiovascular health and disease. Mayo Clin Proc 2009, 84:822–830.CrossRefPubMed
13.
Zurück zum Zitat Esler M, Jennings G, Lambert G: Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 1989, 2:140 S–146S.PubMed Esler M, Jennings G, Lambert G: Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 1989, 2:140 S–146S.PubMed
14.
Zurück zum Zitat Converse RL Jr, Jacobsen TN, Toto RD, et al.: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327:1912–1918.PubMed Converse RL Jr, Jacobsen TN, Toto RD, et al.: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327:1912–1918.PubMed
15.
Zurück zum Zitat Schlaich MP, Lambert E, Kaye DM, et al.: Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 2004, 43:169–175.CrossRefPubMed Schlaich MP, Lambert E, Kaye DM, et al.: Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 2004, 43:169–175.CrossRefPubMed
16.
Zurück zum Zitat •• Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275–1281. This is the initial proof-of-concept trial demonstrating that catheter-based renal denervation using radiofrequency energy as a therapeutic strategy decreased blood pressure in 45 patients with resistant hypertension. •• Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275–1281. This is the initial proof-of-concept trial demonstrating that catheter-based renal denervation using radiofrequency energy as a therapeutic strategy decreased blood pressure in 45 patients with resistant hypertension.
17.
Zurück zum Zitat Schlaich MP, Sobotka PA, Krum H, et al.: Renal denervation as a therapeutic approach for hypertension. Novel implications for an old concept. Hypertension 2009, 54:1195–1201. Schlaich MP, Sobotka PA, Krum H, et al.: Renal denervation as a therapeutic approach for hypertension. Novel implications for an old concept. Hypertension 2009, 54:1195–1201.
18.
Zurück zum Zitat DiBona GF, Kopp UC: Neural control of renal function. Physiol Rev 1997, 77:75-197.PubMed DiBona GF, Kopp UC: Neural control of renal function. Physiol Rev 1997, 77:75-197.PubMed
19.
Zurück zum Zitat DiBona GF: Neural control of the kidney: past, present and future. Hypertension 2003, 41:621–624.CrossRefPubMed DiBona GF: Neural control of the kidney: past, present and future. Hypertension 2003, 41:621–624.CrossRefPubMed
20.
Zurück zum Zitat Kirchheim H, Ehmke H, Persson P: Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr 1989, 67:858–864.CrossRefPubMed Kirchheim H, Ehmke H, Persson P: Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr 1989, 67:858–864.CrossRefPubMed
21.
Zurück zum Zitat Zanchetti AS: Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation 1977, 56:691–698.PubMed Zanchetti AS: Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation 1977, 56:691–698.PubMed
22.
Zurück zum Zitat Holmer S, Rinne B, Eckardt KU, et al.: Role of renal nerves for the expression of renin in adult rat kidney. Am J Physiol 1994, 266:F 738–F 745. Holmer S, Rinne B, Eckardt KU, et al.: Role of renal nerves for the expression of renin in adult rat kidney. Am J Physiol 1994, 266:F 738–F 745.
23.
Zurück zum Zitat Schultz HD, Li YL, Ding Y: Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure. Hypertension 2007, 50:6–13.CrossRefPubMed Schultz HD, Li YL, Ding Y: Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure. Hypertension 2007, 50:6–13.CrossRefPubMed
24.
Zurück zum Zitat Katholi RE, Hageman GR, Whitlow PL, et al.: Hemodynamic and afferent renal nerve responses to intrarenal adenosine in the dog. Hypertension 1983, 5(Supp I):I-149–I-154. Katholi RE, Hageman GR, Whitlow PL, et al.: Hemodynamic and afferent renal nerve responses to intrarenal adenosine in the dog. Hypertension 1983, 5(Supp I):I-149–I-154.
25.
Zurück zum Zitat Katholi RE, Whitlow PL, Hageman GR, et al.: Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertension 1984, 2:349–359. Katholi RE, Whitlow PL, Hageman GR, et al.: Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertension 1984, 2:349–359.
26.
Zurück zum Zitat •• Schlaich MP, Sobotka PA, Krum H, et al.: Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361:932–934. This case report demonstrates that bilateral renal denervation by radiofrequency ablation in a patient with resistant hypertension results in functionally decreased renal efferent and afferent nerve activity. •• Schlaich MP, Sobotka PA, Krum H, et al.: Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361:932–934. This case report demonstrates that bilateral renal denervation by radiofrequency ablation in a patient with resistant hypertension results in functionally decreased renal efferent and afferent nerve activity.
27.
Zurück zum Zitat Schlaich M, Krum H, Walton T, et al.: A novel catheter based approach to denervate the human kidney reduces blood pressure and muscle sympathetic nerve activity in a patient with end stage renal disease and hypertension. J Hypertension 2009, 27(suppl 4):s437. Schlaich M, Krum H, Walton T, et al.: A novel catheter based approach to denervate the human kidney reduces blood pressure and muscle sympathetic nerve activity in a patient with end stage renal disease and hypertension. J Hypertension 2009, 27(suppl 4):s437.
28.
Zurück zum Zitat Katholi RE, Carey RM, Ayers CR, et al.: Production of sustained hypertension by chronic intrarenal norepinephrine infusion in conscious dogs. Circ Res 1977, 40(Suppl I):118–126. Katholi RE, Carey RM, Ayers CR, et al.: Production of sustained hypertension by chronic intrarenal norepinephrine infusion in conscious dogs. Circ Res 1977, 40(Suppl I):118–126.
29.
Zurück zum Zitat Baumbach G: Mechanisms of vascular remodeling. In Hypertension Primer, edn 3. Edited by Isso JL, Black HR. Philadephia, PA: Lippincott Williams & Wilkins; 2003:180–183. Baumbach G: Mechanisms of vascular remodeling. In Hypertension Primer, edn 3. Edited by Isso JL, Black HR. Philadephia, PA: Lippincott Williams & Wilkins; 2003:180–183.
30.
Zurück zum Zitat Fletcher EC. Invited review: Physiological consequences of intermittent hypoxia: systemic blood pressure. J Appl Physiol 2001, 90:1600–1605.CrossRefPubMed Fletcher EC. Invited review: Physiological consequences of intermittent hypoxia: systemic blood pressure. J Appl Physiol 2001, 90:1600–1605.CrossRefPubMed
31.
Zurück zum Zitat Sherwood A, Steffen PR, Blumenthal JA, et al.: Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hypertens 2002, 15:111–118.CrossRefPubMed Sherwood A, Steffen PR, Blumenthal JA, et al.: Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hypertens 2002, 15:111–118.CrossRefPubMed
32.
Zurück zum Zitat Grassi G, Seravalle G, Quarti-Trevano F, et al.: Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008, 52:925–931.CrossRefPubMed Grassi G, Seravalle G, Quarti-Trevano F, et al.: Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008, 52:925–931.CrossRefPubMed
33.
Zurück zum Zitat Kopp UC, Cicha MZ, Smith LA, et al.: Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol 2007, 293(4):R1561–R1572.PubMed Kopp UC, Cicha MZ, Smith LA, et al.: Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol 2007, 293(4):R1561–R1572.PubMed
34.
Zurück zum Zitat Kopp UC, Olson LA, DiBona GF: Renorenal reflex responses to mechano- and chemoreceptor stimulation in the dog and rat. Am J Physiol Renal Fluid Electrolyte 1984, 246:F67–F77. Kopp UC, Olson LA, DiBona GF: Renorenal reflex responses to mechano- and chemoreceptor stimulation in the dog and rat. Am J Physiol Renal Fluid Electrolyte 1984, 246:F67–F77.
35.
Zurück zum Zitat Katholi RE, Taylor GJ, McCann WP, et al.: Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995, 195:17–22.PubMed Katholi RE, Taylor GJ, McCann WP, et al.: Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995, 195:17–22.PubMed
36.
Zurück zum Zitat McQueen DS, Ribeiro JA: Effect of adenosine on carotid chemoreceptor activity in the cat. Br J Pharmacol 1981, 74:129–136PubMed McQueen DS, Ribeiro JA: Effect of adenosine on carotid chemoreceptor activity in the cat. Br J Pharmacol 1981, 74:129–136PubMed
37.
Zurück zum Zitat Peet MM: Results of subdiaphragmatic splanchnicectomy for arterial hypertension. N Engl J Med 1947, 236:270–276.PubMedCrossRef Peet MM: Results of subdiaphragmatic splanchnicectomy for arterial hypertension. N Engl J Med 1947, 236:270–276.PubMedCrossRef
38.
Zurück zum Zitat Morrissey DM, Brooks VS, Cooke WT: Sympathectomy in the treatment of hypertension: review of 122 cases. Lancet 1953, 1:403–408.CrossRefPubMed Morrissey DM, Brooks VS, Cooke WT: Sympathectomy in the treatment of hypertension: review of 122 cases. Lancet 1953, 1:403–408.CrossRefPubMed
39.
Zurück zum Zitat Smithwick RH, Thompson JE: Splanchnicectomy for essential hypertension: results in 1,266 cases. J Am Med Assoc 1953, 152:1501–1504.PubMed Smithwick RH, Thompson JE: Splanchnicectomy for essential hypertension: results in 1,266 cases. J Am Med Assoc 1953, 152:1501–1504.PubMed
40.
Zurück zum Zitat Evelyn KA, Singh MM, Chapman WP, et al.: Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med 1960, 28:188–221.CrossRefPubMed Evelyn KA, Singh MM, Chapman WP, et al.: Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med 1960, 28:188–221.CrossRefPubMed
41.
Zurück zum Zitat DiBona GF: Renal innervation and denervation: lessons from renal transplantation reconsidered. Artif Organs 1987, 11:457–462.PubMed DiBona GF: Renal innervation and denervation: lessons from renal transplantation reconsidered. Artif Organs 1987, 11:457–462.PubMed
42.
Zurück zum Zitat Wustmann K, Kucera JP, Scheffers I, et al.: Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009, 54:530–536.CrossRefPubMed Wustmann K, Kucera JP, Scheffers I, et al.: Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009, 54:530–536.CrossRefPubMed
43.
Zurück zum Zitat Gordon RD, Bachman AW, Jackson RV, et al.: Increased sympathetic activity in renovascular hypertension in man. Clin Exp Pharmacol Physiol 1982, 9:277–281.PubMed Gordon RD, Bachman AW, Jackson RV, et al.: Increased sympathetic activity in renovascular hypertension in man. Clin Exp Pharmacol Physiol 1982, 9:277–281.PubMed
44.
Zurück zum Zitat Katholi RE, Sobotka PA, Schlaich MP, et al.: The role of the renal nerves in cardiorenal syndrome in heart failure. In The Cardiorenal Syndrome: A Clinician’s Guide to Pathophysiology and Management. Edited by Heywood JT, Burnett JC Jr. Minneapolis, MN: Cardiotext Publishing; in press. Katholi RE, Sobotka PA, Schlaich MP, et al.: The role of the renal nerves in cardiorenal syndrome in heart failure. In The Cardiorenal Syndrome: A Clinician’s Guide to Pathophysiology and Management. Edited by Heywood JT, Burnett JC Jr. Minneapolis, MN: Cardiotext Publishing; in press.
45.
Zurück zum Zitat Kearney PM, Whelton M, Reynolds K, et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217–223.PubMed Kearney PM, Whelton M, Reynolds K, et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217–223.PubMed
46.
Zurück zum Zitat • Sarafidis, PA, Bakris GL: Resistant hypertension. An overview of evaluation and treatment. J Am Coll Cardiol 2008, 52:1749–1757. This is a state-of-the-art paper on the definition and prevalence of resistant hypertension. An overview on the evaluation and treatment of this relatively common clinical problem is included. • Sarafidis, PA, Bakris GL: Resistant hypertension. An overview of evaluation and treatment. J Am Coll Cardiol 2008, 52:1749–1757. This is a state-of-the-art paper on the definition and prevalence of resistant hypertension. An overview on the evaluation and treatment of this relatively common clinical problem is included.
47.
Zurück zum Zitat Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925–930.CrossRefPubMed Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925–930.CrossRefPubMed
48.
Zurück zum Zitat Williams EM, Katholi RE, Karambelas MR: Use and side-effect profile of spironolactone in a private cardiologist’s practice. Clin Cardiol 2006, 29:149–153.CrossRefPubMed Williams EM, Katholi RE, Karambelas MR: Use and side-effect profile of spironolactone in a private cardiologist’s practice. Clin Cardiol 2006, 29:149–153.CrossRefPubMed
49.
Zurück zum Zitat Flaa A, Aksnes TA, Kjeldsen SE, et al.: Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Metabolism Clin Experi 2008, 57:1422–1427. Flaa A, Aksnes TA, Kjeldsen SE, et al.: Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Metabolism Clin Experi 2008, 57:1422–1427.
50.
Zurück zum Zitat Burns J, Sivananthan MU, Ball SG, et al.: Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circ 2007, 115:1999–2005.CrossRef Burns J, Sivananthan MU, Ball SG, et al.: Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circ 2007, 115:1999–2005.CrossRef
Metadaten
Titel
Renal Nerves in the Maintenance of Hypertension: A Potential Therapeutic Target
verfasst von
Richard E. Katholi
Krishna J. Rocha-Singh
Nilesh J. Goswami
Paul A. Sobotka
Publikationsdatum
01.06.2010
Verlag
Current Science Inc.
Erschienen in
Current Hypertension Reports / Ausgabe 3/2010
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-010-0108-4

Weitere Artikel der Ausgabe 3/2010

Current Hypertension Reports 3/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.